EUVIMEDEUVIMED entdecken
Crossref

Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia

Matthew W Hruska iD, Lamia Sid-Otmane, Nathalie H Gosselin, Emilia Quattrocchi iD, Sun Ku Lee, Mary Ann Mascelli, Krina Mehta, Suzanne M Jan de Beur iD, Douglas Marsteller

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Matthew W Hruska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kyowa Kirin Inc., Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Osteomalacia, Antibodies, Monoclonal, Humanized, Models, Biological. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Kyowa Kirin, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Burosumab is approved for the treatment of hypophosphatemia in persistent tumor‐induced osteomalacia. This work exemplifies a model‐informed drug development approach that evaluated burosumab pharmacokinetics and pharmacokinetic/pharmacodynamics in the ultrarare tumor‐induced osteomalacia population to support adult and pediatric dosing. Data from tumor‐induced osteomalacia participants were combined with data from X‐linked hypophosphatemia to understand pharmacokinetic and pharmacokinetic/pharmacodynamic characteristics and covariates specific to tumor‐induced osteomalacia. Pharmacokinetic and pharmacokinetic/pharmacodynamic simulations were performed using final models to support dosing recommendations for adults and extrapolation to pediatric patients. Burosumab pharmacokinetics were described using a one‐compartment model with first‐order absorption and body weight as a significant covariate. Pharmacokinetic/pharmacodynamic relationships were described using a sigmoidal Emax model with significant covariates of baseline fibroblast growth factor 23 on baseline fasting serum phosphate and potency of burosumab response and tumor‐induced osteomalacia disease state resulting in a steep slope of response; however, the covariates are not clinically meaningful. Simulations demonstrated that, in pediatric patients, starting doses of burosumab 0.3 and 0.4 mg/kg every 2 weeks at steady state would achieve normal serum phosphate levels in ≥ 30% of patients with relatively low risk of hyperphosphatemia (< 3%). In adults, burosumab 0.3 and 0.5 mg/kg every 4 weeks achieves similar percentages of responders and a relative low risk of hyperphosphatemia (< 7%). Serum phosphate titration‐based burosumab dosing increased the probability of achieving normal serum phosphate levels. The models supported a model‐informed drug development approach for global approvals of titration‐based burosumab dosing, guided by monitoring fasting serum phosphate levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteomalaciaAntibodies, Monoclonal, HumanizedModels, BiologicalHumansChildAdultMaleFemaleAdolescentFibroblast Growth Factor-23Young AdultParaneoplastic SyndromesDose-Response Relationship, DrugMiddle AgedNeoplasms, Connective TissueFibroblast Growth FactorsPhosphatesChild, PreschoolComputer Simulation

Substanzen

burosumabAntibodies, Monoclonal, HumanizedFibroblast Growth Factor-23Fibroblast Growth FactorsPhosphates

Autor:innen und Institutionen

  • Kyowa Kirin Inc., Princeton, New Jersey, USA.
  • Certara Drug Development Solutions, Princeton, New Jersey, USA.
  • Kyowa Kirin Pharmaceutical Development Ltd, Marlow, UK.
  • Morphic Therapeutic, Waltham, Massachusetts, USA.
  • Chinook Therapeutics Inc, Seattle, Washington, USA.
  • Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Matthew W Hruska, Emilia Quattrocchi, Suzanne M Jan de Beur

Förderung

  • Kyowa Kirin, Inc.

Zitieren

APA

Hruska, M. W., Sid-Otmane, L., Gosselin, N. H., Quattrocchi, E., Lee, S. K., Mascelli, M. A., Mehta, K., Jan de Beur, S. M., & Marsteller, D. (2024). Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3468

Vancouver

Hruska MW, Sid-Otmane L, Gosselin NH, Quattrocchi E, Lee SK, Mascelli MA, et al. Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3468

BibTeX
@article{Hruska2024,
  author = {Hruska, Matthew W and Sid-Otmane, Lamia and Gosselin, Nathalie H and Quattrocchi, Emilia and Lee, Sun Ku and Mascelli, Mary Ann and Mehta, Krina and Jan de Beur, Suzanne M and Marsteller, Douglas},
  title = {Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3468}
}
Kostenlos starten →